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COMPARISON OF INDAPAMIDE 
AND LOW-DOSE 
HYDROCHLOROTHIAZIDE 
MON01LHERAPY IN BLACK 
PATIENTS WITH MILD TO 
MODERATE HYPERTENSION 
Ivelin V Radevski, Zdravka P Valtchanova, Geoffrey P 
Candy, Anthony M Wald, Thandeka Ngcezula, Pinchas Sareli 
Objectives. 1o assess, using ambulatory blood pressure 
monitoring (ABPM), the antihypertensive efficacy of 
hydrochlorothiazide 12.5 mg and indapamide 2.5 mg given 
as a monotherapy over 3 months to black patients with 
mild to moderate essential hypertension. 
Design. Single-centre, prospective, randomised open pilot 
study in three phases: (i) 1-week drug-free washout period; 
(ii) 2-week placebo run-in phase; and (iii) 3-month 
prospective open-label active treatment period. 
Results. Forty-two black patients with mean daytime 
diastolic BP (DBP) ~ 90 mmHg and ~ 115 mmHg (mean age 
57± 11 years, 28 women/14 men) were enrolled into the 
study. Overall, a profound and sustained BP reduction was 
achieved with indapamide at 3 months (N = 20). The 
24-hour BP decreased from 150 ± 17/94 ± 6 mmHg to 
130 ± 19/82 ± 9 mmHg (P < 0.0001 for systolic BP (SBP) 
and DBP at 3 months versus baseline); the mean daytime 
BP decreased from 155 ± 15/98 ± 6 mmHg to 134 ± 18/87 
± 10 mmHg (P < 0.0001 for SBP and DBP at 3 months 
versus baseline). The overall control (mean daytime DBP 
< 90 mmHg) and response (decrease in daytime DBP ~ 10 
mmHg) rates achieved with indapamide were 10/20 (50%) 
and 13/20 (65%), respectively. In contrast, monotherapy 
with hydrochlorothiazide resulted in more modest BP 
reduction and control and response rates at 3 months 
(N = 22). The 24-hour BP decreased from 147 ± 14/94 ± 7 
mmHg to 139 ± 19/88 ± 2 mmHg (P < 0.05 forDBPat3 
months versus baseline, P = NS for SBP); the mean daytime 
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BP decreased from 151 ± 14/98 ± 5 mmHg to 144 ± 16/93 
± 10 mmHg (P < 0.05 for DBP at 3 months versus baseline, P 
= NS for SBP). The corresponding control and response rates 
were 7/22 (32%) and 8/22 (36%). Both hydrochlorothiazide 
and indapamide caused significant hypokalaemia. 
Conclusions. Monotherapy with indapamide is associated with 
greater BP reduction and control and response rates than 
monotherapy with low-dose hydrochlorothiazide and may be 
an appropriate choice of antihypertensive diuretic therapy in 
black South African patients with mild to moderate 
hypertension. 
S Afr Med J 2002; 92: 532-536. 
Low-dose thiazide diuretics are widely recommended as 
first-line antihypertensive therapy in mild to moderate 
hypertension.'.2 It has been shown, using ambulatory blood 
pressure (BP) monitoring (ABPM), that their short-term 
(3 months) BP-lowering effect as monotherapy in black South 
African hypertensives is modest.' However, their long-term 
efficacy in this population is not well established. Also, the role 
of other diuretics such as indapamide as first-line agents in the 
management of mild to moderate hypertension in such patients 
is not well documented. 
In the present study, using ABPM in 42 mild to moderate 
black South African hypertensive patients, we assessed the 
antihypertensive efficacy of low-dose hydrochlorothiazide 
12.5 mg daily (Dichlotride, Merck Sharpe & Dohme) and 
indapamide 2.5 mg daily (Natrilix, Servier Laboratories), given 
once daily as monotherapy over 3 months. 
METHODS 
Patient population 
Included in the study were black patients with mild to 
moderate hypertension who met two entry BP criteria, namely 
an average sitting DBP ~ 95 and < 115 mmHg, measured as a 
mean of 10 readings over a 30-minute period using a Dinamap 
device (Critikon 1846 SX Vital Signs Monitor), and a mean 
daytime ambulatory DBP ~ 90 mmHg and < 115 mmHg. The 
BP measurements were, therefore, free of observer bias. Eligible 
patients of either sex with essential mild to moderate 
hypertension (either newly diagnosed or not adequately 
controlled previously) were entered into the study after a 
1-week washout period (for patients not controlled on their 
current therapy), followed by a 2-week placebo run-in phase; 
they were then randomised to 3 months' therapy with active 
medication. Laboratory tests and 24-hour electrocardiogram 
(ECG) Holter monitoring were performed at baseline and 3 
months to assess the safety of the study medications and their 
effect on the incidence of arrhythmia. 
Exclusion criteria were as follows: pregnant or lactating 
women, DBP ~ 115 mmHg, SBP > 200 mmHg, secondary 
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hypertension, myocardial infarction or cerebrovascular 
insufficiency within the 3 months preceding enrolment, cardiac 
arrhythmias, insulin-dependent diabetes mellitus, clinically 
significant alteration in renal or liver function, electrolyte 
abnormalities, hyperuricaemia, clinically significant depression 
6 months before enrolment, history of alcohol or drug abuse, 
unco-operative or antagonistic personality, or previous history 
of intolerance to any of the study drugs. 
All patients gave written informed consent before enrolment. 
The trial protocol was approved by the Committee for Research 
on Human Subjects of the University of the Witwatersrand and 
the Pharmacy and Therapeutics Committee of Chris Hani-
Baragwanath Hospital, Johannesburg. 
Study design 
This single-centre, prospective, randomised, open pilot study 
included three phases: (i) a 1-week drug-free wash-out period; 
(ii) a 2-week placebo run-in phase to identify placebo 
responders; and (iii) a 3-month prospective open-label active 
treatment period. All eligible patients were randomised 1:1 to 
either hydrochlorothiazide 12.5 mg daily or indapamide 2.5 mg 
daily, for 3 months. Twenty-four-hour ABPM was performed at 
baseline and after 3 months of diuretic therapy. 
Compliance assessment by tablet count was performed at 
each monthly visit. All patients showed good compliance with 
the therapy (80- 120%) throughout the study. 
BP measurement 
Office BP was measured following the recommendations of the 
American Heart Association.' 
By using the Dinamap Critikon 1846 SX vital signs monitor, 
BP was measured every 3 minutes for up to 30 minutes. The 
monitors were calibrated against mercury sphygmomano-
meters, with a maximum acceptable difference of ± 5 mmHg at 
200 mmHg.' The reason for using the Dinamap as a screening 
device was to eliminate observer bias and white-coat 
hypertension as much as possible. 
Twenty-four-hour ABPM was performed using Space Labs 
90207 oscilliometric BP monitors calibrated against a mercury 
sphygmomanometer before use in each patient, with monitor 
readings being within 3 mmHg or2% of the manometer 
readings, whichever was greater.' Monitors were programmed 
to read BP and heart rate (HR) every 15 minutes from 06h00 to 
18h00 and every 20 minutes from 18h00 to 06h00. Mean 
daytime (06h00 - 18h00) and night-time (18h00 - 06h00) BP and 
HR were calculated. 
Trough and peak ratio measurement using ABPM 
The average of two consecutive hours of maximum BP 
lowering during the day was defined as peak effect. The 
average of the last 2 hours of the 24-hour period was defined 
as trough effect. Only responding patients were included in the 
trough-to-peak analysis (reduction in mean daytime DBP 
<': 10 mmHg). 
Microalbumin excretion rate 
Twenty-four-hour urine samples were collected at baseline and 
at the end of study and sent to the laboratory for microalbumin 
measurement. Microalbuminuria was defined as a 
microalbumin excretion rate between 30 and 300 mg per 24 
hours. 
Ambulatory ECG Holter monitoring 
Ambulatory ECG Holter recordings were performed over a 24-
hour period using SpaceLabs 90205 portable tape recorders. 
The complete 24-hour record was printed with a Spacelabs FT 
3000 full-disclosure unit. The printouts were analysed by an 
experienced technologist, who was blinded to the results of 
other investigations or the patient's treatment. Patients were 
categorised according to the maximum absolute number of 
ventricular extrasystoles in any single hour during the 24-hour 
monitoring. The occurrence at any stage of multifocal 
ventricular premature beats (VPBs), ventricular couplets or 
ventricular tachycardia was also documented. 
Statistical analysis 
Results are presented as mean± standard deviation (SD). 
Continuous data were analysed using the Student's t-test, 
ANOVA and MANOVA tests. When no proof of normality was 
available, non-parametric tests, i.e. Wilcoxon's matched pairs 
signed-rank test and the Kruskal-Wallis and Friedman tests, 
were used for between- and within-group comparisons. A P-
value of < 0.05 was considered significant for all statistical 
tests. 
RESULTS 
Table I summarises the baseline demographic characteristics 
for the study population. The patients were mostly female with 
a high body mass index. It is important to note that 9 I 42 
patients (21 %) had non-insulin-dependent diabetes mellitus 
and 6/42 patients (14%) had microalbuminuria. No patients 
had been taking reserpine as part of medication before this 
study. 
Table II shows the BP-lowering effect of both diuretics, using 
24-hour ABPM and Dinamap. Monotherapy with indapamide 
was associated with significant reduction in Dinamap SBP and 
DBP (25 and 11 mmHg, respectively), with no clinically 
apparent effect on the HR. The BP response, measured by 24-
hour ABPM, is consistent with the above observation, with 
reduction of SBP and DBP of 20 and 12 mmHg, respectively. In 
contrast, the antihypertensive effect of hydrochlorothiazide liD 
was more modest (P = 0.05 for indapamide versus 
hydrochlorothiazide at 3 months). The reduction in 24-hour 
SBP achieved with hydrochlorothiazide (8 mmHg) was not 
significant, but the DBP reduction (6 mmHg) reached statistical 
significance. 
The above differences in overall BP-lowering effect between 
low-dose hydrochlorothiazide and indapamide are reflected in 
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Table I. Demographic data 
All patients 
(N = 42) 
Age (yrs) 57(11)* 
Male/female (N) 14/28 
BMI (kg/m') 31 (8)* 
Hypertension 
duration (yrs) 5.5 (5.8)* 
Newly diag-
nosed (N (%) 7 (17) 
Previously tJreated 
with hydrochlo-
rothiazide (N (%)) 12 (28.6) 
Type II diabetes 
mellitus (N (%)) 9 (21) 
Microalbuminuria 
(N (%)) 6 (14) 
Smokers,> !i cigarettes/ 
day (N (%)) 8 (19) 
Alcohol use,. 1- 7 drinks/ 
week (N (%)) 6 (14) 
* Mean and standard deviation. 



























the control (mean daytime DBP < 90 mmHg) and response 
(reduction in mean daytime DBP ~ 10 mmHg) rates as shown 
in Table Ill. The response rate was 8/22 (36%) for 
hydrochlorothiazide and 13/20 (65%) for indapamide (P < 0.01 
indapamide versus hydrochlorothiazide). The corresponding 
control rates for hydrochlorothiazide and indapamide were 
7/22 (32%) and 10/20 (50%), respectively (P < O.Dl indapamide 
versus hydrochlorothiazide). Furthermore, the antihyperten-
sive effect of hydrochlorothiazide and indapamide was sus-
tained over the 24-hour period (Figs 1 and 2), with good 
trough-to-peak ratios for both SBP and DBP in responding 
patients. 
Table IV documents the effect of the different diuretic 
therapies on biochemical parameters, showing significant 
decrease in potassium level for both groups. No other 
significant biochemical abnormalities were detected. Neither of 
the study medications had an effect on the microalbumin 
excretion rate. 
The incidence of ventricular arrhythmic events is shown in 
Table V. None of the study drugs had any effect on the 
incidence of arrhythmic events. No sustained ventricular 
tachycardia was observed at baseline and end of treatment. 
DISCUSSION 
The major findings of this study are: (i) monotherapy with 
indapamide was associated with significantly greater reduction 
Table II. Blood pressure and heart rate at baseline and after 3 months of diuretic monotherapy (mean val~es and standard deviation) 
Hydrochlorothiazide (12.5 mg/ d, N = 22) Indapamide (2.5 mg/ d, N = 20) 
SBP (mmHg) DBP (mmHg) SBP (mmHg) DBP (mmHg) 
Dinamap BP (mmHg) 
Baseline 154 (16) 96 (8) 161 (13) 97 (9) 
3months 146 (19) 92 (10) 136 (20)* 86 (lO)t 
24-hour BP (mmHg) 
Baseline 147 (14) 94 (7) 150 (17) 94 (6) 
3 months 139 (19) 88 (12)+ 130 (19)+ 82 (9):1: 
Daytime BP (mmHg) 
Baseline 151 (14) 98 (5) 155 (15) 98 (6) 
3months 144 (16) 93 om+ 134 (18)* 87 (10):1:§ 
Night-time BP (mmHg) 
Baseline 142 (15) 89 (9) 141 (24) 87 (7) 
3 months 133 (23) 82 (15) 125 (21)+ 76 (8):1: 
24-hour heart rate (bpm) 
Baseline 78 (10) 76 (13) 
3 months 79 (9) 78 (14) 
Day-time heart rate (bpm) 
Baseline 82 (11) 80 (14) 
3 months 83 (10) 81 (15) 
Night-time heart rate (bpm) 
Baseline 74 (9) 72 (13) 
3months 74 (9) 75 (14)) 
* P < 0.002 at 3 months versus baseline. 
t P < 0.05 at 3 months versus baseline. * P < 0.0001 at 3 months versus baseline. 
§ P < 0.05 indapamide versus hydrochlorothiazide at 3 months of monotherapy. 
bpm :::;; beats pE!r minute. 
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Table III. Control (mean daytime DBP < 90 mmHg) and response 
(reduction in mean daytime DBP ~ 10 mmHg) rates and trough-to-
peak ratios in responding patients after 3 months of monotherapy 















* P < 0.01 indapamide versus hydrochlorothiazide. 
SD :::= standard deviation. 
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Fig. 1. Twenty-four-hour blood pressure profiles at baseline 
and after 3 months of therapy with indapamide 2.5 mg 
once daily (N = 20). 
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Fig. 2. Twenty1our-hour blood pressure profiles at baseline 
and after 3 months of therapy with hydrochlorothiazide 12.5 
mg once daily (N = 22). 
of SBP and DBP at 3 months compared with low-dose 
hydrochlorothiazide in mild to moderate black South African 
hypertensives; (ii) there was a significant decrease in serum 
potassium levels after 3 months of diuretic monotherapy, 
observed with both agents; and (iii) neither of the study drugs 
was associated with increased incidence of arrhythmias. 
Low-dose thiazide diuretics have been recommended and 





Table IV. Changes in biochemical parameters following 3 months 
of diuretic monotherapy (mean values and standard deviation) 
Hydrochlo-
rothiazide Indapamide 
(N = 22) (N = 20) 
Sodium (mmol/1) 
Baseline 141 (4) 141 (5) 
3 months 140 (5) 139 (4) 
Potassium (mmol/1) 
Baseline 4.3 (0.6) 4.2 (0.5) 
3 months 3.8 (0.6)* 3.6 (0.6)t 
Creatinine (J.lmol/1) 
Baseline 72 (14) 77 (22) 
3 months 72 (12) 88 (10) 
Glucose (mmol/1) 
Baseline 4.5 (0.5) 5.1 (1.6) 
3 months 4.6 (0.9) 5.1 (1.1) 
Total cholesterol (mmol/1) 
Baseline 5.0 (1.4) 4.9 (l.D) 
3 months 5.20 (1.4) 5.1 (1.0) 
LDL (mmol/1) 
Baseline 2.8 (1.2) 2.9 (1.0) 
3 months 3.0 (1.3) 3.0 (1.2) 
HDL (mmol/1) 
Baseline 1.5 (0.9) 1.2 (0.3) 
3 months 1.4 (0.3) 1.3 (0.4) 
Triglycerides (mmol/1) 
Baseline 1.6 (0.6) 1.9 (0.9) 
3 months 1.7 (0.8) 2.0 (1.0) 
Microalbuminuria (N) 
Baseline 4 2 
3 months 4 4 
* P < 0.05 at 3 months versus baseline. 
t P < 0.005 at 3 months versus baseline. 
LDL = low-density lipoprotein; HDL = high-density lipoprotein. 
moderate hypertension in this population. However, their 
efficacy as a monotherapy is, at best, modest and many black 
hypertensive patients require combination antihypertensive 
therapy. Materson et al.'-' have shown that in young African-
American patients with mild to moderate hypertension office 
DBP of less than 90 mmHg at 1 year was achieved in only 42% 
of patients, using 12.5 - 50 mg hydrochlorothiazide. 
Furthermore, using low-dose hydrochlorothiazide (12.5 mg), 
the above goal was reached in only 35% of patients. In the 
present study, using 24-hour ABPM, we found that a low-dose 
thiazide diuretic achieved BP control in 32% of the patients at 3 
months, with a response rate of 36%. In comparison, therapy 
with indapamide was associated with greater BP reduction and 
higher control (50%) and response (65%) rates. Furthermore, liiJ 
the BP reduction achieved with indapamide was greater than 
that achieved with hydrochlorothiazide (P = 0.05 indapamide 
versus hydrochlorothiazide at 3 months). Our decision to use 
hydrochlorothiazide 12.5 mg rather than 25 mg daily is 
justified by the findings of Skoularigis et al.' in a similar group 
of patients, who showed that the increase in the hydrochloro-
1m 
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Table V. Incidence of ventricular arrhythmia events at baseline, 3 
months, and at end of study (number of patients) 
VPB < 10/hour 
Baseline 
3 months 
VPB 10- 30/hour 
Baseline 
3 months 

































VPB = ventricular premature beats; VT ventricular tachycardia. 
thiazide dose from 12.5 to 25 mg daily did not have any 
additional significant effect on BP, but worsened the 
hypokalaemla. Therefore, based on these results, indapamide 
may be an appropriate choice of antihypertensive diuretic 
therapy in black South African patients with mild to moderate 
hypertension. Both study medications were well tolerated, with 
no serious adverse events or deaths observed. However, serum 
potassium levels should be monitored throughout therapy with 
both diuretics and potassium supplementation should be given 
where necessary. 
We have referred to black patients as this was our study 
population at Chris Hani-Baragwanath Hospital. Patients of 
African descent respond differently to Caucasians when given 
antihyperten:;ive medication, and this is well documented in the 
literature. As black patients suffer more from the effects of 
hypertension - end-stage renal failure, heart failure, etc. - it is 
important to determine causes and optimal treatment in this high-
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DIABETES IN RURAL SOUTH 
AFRICA- AN ASSESSMENT OF 
CARE AND COMPLICATIONS 
A P Rotchford, K M Rotchford 
Objectives. To describe the diabetic population under care of 
the public health sector in a district in rural KwaZulu-Natal, 
to assess the nature of their care, their glycaemic control 
and the extent of their complications. 
Subjects and methods. Two hundred and fifty-three diabetic 
patients consecutively attending clinics for review were 
interviewed and examined, and where available a 12-
month retrospective review of clinical records was 
performed. Random blood glucose, haemoglobin A1, 
(HbA1,) and urine albumin/ creatinine ratio were assayed. 
Results. Acceptable glycaemic control (HbA1, < 2% above 
normal population range) was found in only 15.7% of 
subjects (95% confidence interval (CI): 11.4- 20.8%). Mean 
HbA1, was 11.3%. The prevalence of hypertension (blood 
pressure~ 160/95 mmHg and/or prescribed antihyper-
tensive medication) was 65.4% (CI: 59.0 - 71.1 %). Of 129 
patients who were prescribed antihypertensives, 14.0% (CI: 
8.5- 21.2%) were normotensive(< 140/90 mmHg). Severe 
obesity was present in 36.5% (CI: 30.4- 42.9%). Rates of 
attendance for review and compliance with diabetic 
medications were high. Blood glucose monitoring was not 
regularly performed and medications were rarely modified. 
Complications were common and mostly undiagnosed. 
Retinopathy of any grade was found in 40.3% of patients 
(CI: 33.2- 50.9%) and was severe enough to warrant laser 
photocoagulation in 11.1% (CI: 8.5- 21.2%). 
Microalbuminuria was found in 46.4% (CI: 40.0 - 53.0%) 
and foot abnormalities attributable to diabetes in 6.0% (CI: 
3.4- 9.7%). 
Conclusions. Care and control of diabetes in this rural 
community is suboptimal. There is a need for primary care 
staff to focus on modifying prescriptions in the face of poor 
blood glucose control and/ or uncontrolled hypertension. 
Additional training and support for nursing staff and 
education for patients will be central to achieving this level 
of intervention. 
S Afr Med J 2002; 92: 536-541. 
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